Asp32 and Asp228 determine the selective inhibition of BACE1 as shown by docking and molecular dynamics simulations

Eur J Med Chem. 2016 Nov 29:124:1142-1154. doi: 10.1016/j.ejmech.2016.08.028. Epub 2016 Aug 16.

Abstract

Inhibition of β-site amyloid-β-protein precursor cleaving enzyme 1 (BACE1) represents a promising approach for the treatment of Alzheimer's disease (AD). However, the development of a selective BACE1 inhibitor is difficult due to its highly flexible catalytic site and homology to other aspartic proteases, including BACE2 and Cathepsin D (CTSD). Aiming to better understand the structural factors responsible for selective BACE1 inhibition, we performed alignment studies, molecular dynamics (MD) simulations and docking studies to explore the recognition of four selective BACE1 inhibitors by aspartyl proteases. The results show that selective BACE1 inhibition may be due to the formation of strong electrostatic interactions with Asp32 and Asp228 and a large number of hydrogen bonds, π-π and Van der Waals interactions with the amino acid residues located inside the catalytic cavity, which has different volume and shape compared to BACE2 and CTSD. Hindrance effects avoid the accommodation of ligands in the small catalytic site of BACE2, resulting in a lower affinity and the high cavity of CTSD results in the formation of a small number of interactions with the ligands, although they show a similar binding mode with BACE1. These results might help to rationalize the design of selective BACE1 inhibitors.

Keywords: Alzheimer; Beta secretases; Docking molecular dynamics simulations; Molecular modeling.

MeSH terms

  • Aspartic Acid Endopeptidases / antagonists & inhibitors*
  • Aspartic Acid Endopeptidases / chemistry*
  • Aspartic Acid Endopeptidases / metabolism
  • Aspartic Acid*
  • Catalytic Domain
  • Drug Design
  • Hydrogen Bonding
  • Molecular Docking Simulation*
  • Molecular Dynamics Simulation*
  • Protease Inhibitors / chemistry
  • Protease Inhibitors / metabolism*
  • Protease Inhibitors / pharmacology*
  • Substrate Specificity

Substances

  • Protease Inhibitors
  • Aspartic Acid
  • Aspartic Acid Endopeptidases